| Ferroptosis and cancer prognosis | Lifetime | 58 | CN 17 | 98.85 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 59 | CN 7 | 97.96 |
| RNA modifications and cancer | Lifetime | 871 | CN 112 | 98.40 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 840 | CN 74 | 97.04 |
| Biliary and Gastrointestinal Fistulas | Lifetime | 833 | CN 16 | 90.28 |
| RNA modifications and cancer | 2021-2025 | 30 | CN 19 | 99.63 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 6 | CN 4 | 99.06 |
| Ferroptosis and cancer prognosis | 2021-2025 | 33 | CN 24 | 99.36 |
| Cancer-related gene regulation | 2021-2025 | 14 | CN 10 | 98.70 |
| Cancer-related molecular mechanisms research | 2021-2025 | 69 | CN 46 | 99.29 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 49 | CN 24 | 98.02 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | 2021-2025 | 73 | CN 3 | 98.43 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 235 | CN 25 | 97.87 |
| RNA Research and Splicing | 2021-2025 | 158 | CN 52 | 95.58 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 538 | CN 99 | 97.91 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 164 | CN 25 | 96.59 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 361 | CN 61 | 96.99 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 217 | CN 69 | 93.79 |
| Immune cells in cancer | 2021-2025 | 430 | CN 239 | 92.78 |
| Renal cell carcinoma treatment | 2021-2025 | 393 | CN 37 | 94.00 |
| Cancer Mechanisms and Therapy | 2021-2025 | 149 | CN 57 | 91.24 |
| Epigenetics and DNA Methylation | 2021-2025 | 879 | CN 331 | 90.73 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 681 | CN 167 | 93.35 |
| Peptidase Inhibition and Analysis | 2021-2025 | 562 | CN 168 | 90.60 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 416 | CN 86 | 90.85 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 429 | CN 107 | 89.88 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 884 | CN 84 | 88.33 |
| Lung Cancer Research Studies | 2021-2025 | 887 | CN 195 | 90.46 |
| Anesthesia and Neurotoxicity Research | 2021-2025 | 266 | CN 85 | 86.81 |
| Viral-associated cancers and disorders | 2021-2025 | 372 | CN 68 | 88.24 |
| Gastrointestinal disorders and treatments | 2021-2025 | 657 | CN 71 | 85.06 |
| Colorectal and Anal Carcinomas | 2021-2025 | 716 | CN 97 | 85.47 |
| Occupational and environmental lung diseases | 2021-2025 | 412 | CN 52 | 82.27 |
| Management of metastatic bone disease | 2021-2025 | 558 | CN 61 | 78.63 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 528 | CN 11 | 79.53 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 886 | CN 126 | 74.90 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 404 | CN 161 | 71.81 |
| Galectins and Cancer Biology | 2021-2025 | 642 | CN 172 | 70.87 |
| Inflammation biomarkers and pathways | 2021-2025 | 127 | CN 59 | 69.13 |
| Signaling Pathways in Disease | 2021-2025 | 411 | CN 164 | 63.43 |
| Lipid metabolism and disorders | 2021-2025 | 736 | CN 205 | 64.27 |
| Power Systems and Technologies | 2021-2025 | 594 | CN 432 | 59.97 |
| Congenital gastrointestinal and neural anomalies | 2021-2025 | 497 | CN 72 | 61.33 |
| Spinal Hematomas and Complications | 2021-2025 | 807 | CN 150 | 46.54 |
| Hydrogen's biological and therapeutic effects | 2021-2025 | 567 | CN 270 | 37.62 |
